Cleophas T J, van Lier H J, Fennis J F, van 't Laar A
Angiology. 1984 Jan;35(1):29-37. doi: 10.1177/000331978403500104.
In a double blind placebo-controlled cross-over trial of 24 weeks 31 patients with Raynaud's syndrome were treated with the alpha-blocker phenoxybenzamine (10-20 mg daily) and with the combination of the alpha-blocker phenoxybenzamine (10-20 mg daily) and the beta-blocker sotalol (40-80 mg daily). A favourable effect on recovery of finger temperature after finger cooling was demonstrated after alpha-blockade as compared to the before treatment situation. This favourable effect was not different when the group received the combined alpha- and beta-blockade. The blood pressure was not influenced by either of the 2 medications. Fluid retention appeared with alpha-blockade and was absent with combined alpha- and beta-blockade. Decrease of heart rate occurred with alpha- plus beta-blockade and was absent with alpha-blockade alone. Clinical symptoms of Raynaud's syndrome equally were alleviated by the two medications. Common, and equally frequent side effects of the two medications were nasal congestion, disturbed ejaculation and potency, dry mouth, exercise-induced and orthostatic dizziness. We conclude that alpha-blockade is beneficial in Raynaud's syndrome and that additional beta-blockade counteracts the alpha-blocker side-effect fluid retention, reduces the heart rate and thus may prevent alpha-blocker induced tachycardia, and that it does not cause hypotension.
在一项为期24周的双盲安慰剂对照交叉试验中，31名雷诺综合征患者接受了α受体阻滞剂酚苄明（每日10 - 20毫克）治疗，以及α受体阻滞剂酚苄明（每日10 - 20毫克）与β受体阻滞剂索他洛尔（每日40 - 80毫克）联合治疗。与治疗前相比，α受体阻滞治疗后手指冷却后手指温度恢复有良好效果。当该组接受α和β受体联合阻滞时，这种良好效果并无差异。两种药物均未影响血压。α受体阻滞治疗出现了液体潴留，而α和β受体联合阻滞治疗未出现液体潴留。α加β受体阻滞治疗使心率降低，单独α受体阻滞治疗未出现心率降低。两种药物均同样减轻了雷诺综合征的临床症状。两种药物常见且同样频繁出现的副作用有鼻充血、射精及性功能障碍、口干、运动性和体位性头晕。我们得出结论，α受体阻滞对雷诺综合征有益，额外的β受体阻滞可抵消α受体阻滞剂的副作用液体潴留，降低心率，从而可能预防α受体阻滞剂引起的心动过速，且不会导致低血压。
